English
Regional settings| Spread | 0.06 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 7.58 |
| Open | 7.56 |
| 1-Year Change | -33.51% |
| Day's Range | 7.38 - 9.36 |
IGM Biosciences, Inc. is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of multiple diseases. It has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
BRIEF: For the nine months ended 30 September 2021, IGM Biosciences Inc revenues was not reported. Net loss increased from $56.7M to $114.5M. Higher net loss reflects Research and development - Bala increase of 89% to $80.3M (expense), General and administrative - Balanc increase of 67% to $17.1M (expense), Stock-based Compensation in SGA increase from $2.9M to $9.7M (expense).
